Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs iShares Core S&P 500 ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.28 (market cap $12.58B), while iShares Core S&P 500 ETF trades at $781.68 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 71.3× Halozyme Therapeutics Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is more actively traded (4,580,672 versus 2,179,278). Which is the better fit depends on your goals.
| HALO | IVV | |
|---|---|---|
Market Cap | $12.58B | $897.20B |
Volume | 2,179,278 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $115.22 | $782.58 |
52-Week Low | $61.63 | $634.93 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IVV, tracking the S&P 500, trades at $779.68, down 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights mixed S&P 500 valuation signals, with earnings growth expected to slow in 2027 but historical seasonal patterns suggesting potential upside. The ETF's fundamentals reflect the index's aggregate metrics, with no company-specific financials reported.
Outlook remains cautiously optimistic given the bullish technical bias and index-level support, though risks include concentration in top holdings and macroeconomic headwinds. Investors gain diversified exposure to large-cap U.S. equities, but should monitor earnings trends and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
